Related references
Note: Only part of the references are listed.Activity of fosfomycin when tested against US contemporary bacterial isolates
Robert K. Flamm et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model
Arnold Louie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial
Keith S. Kaye et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3-or OXA-48-producing Escherichia coli
M. Berleur et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study
Laura Vallejo-Torres et al.
BMJ OPEN (2018)
The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model
G. L. Drusano et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration
Marguerite L. Monogue et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2018)
Intravenous fosfomycin for the treatment of hospitalized patients with serious infections
Andrew F. Shorr et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2017)
Biological cost of fosfomycin resistance in Escherichia coli in a murine model of urinary tract infection
A. Pourbaix et al.
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY (2017)
Safety Results from the ZEUS Study: Multi-center, Randomized, Double-Blind Phase 2/3 Study in Hospitalized Adults with Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP) Who Received Intravenous Fosfomycin (ZTI-01)
Louis B Rice et al.
Open Forum Infectious Diseases (2017)
In vitro Activity of Fosfomycin, Alone and Combined with Cefepime and Meropenem, Against Carbapenemase-Producing Gram-Negative Bacteria
Nathan P Wiederhold et al.
Open Forum Infectious Diseases (2017)
The Increase in Hospitalizations for Urinary Tract Infections and the Associated Costs in the United States, 1998-2011
Jacob E. Simmering et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers
E. Wenzler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature
B. Grabein et al.
CLINICAL MICROBIOLOGY AND INFECTION (2017)
In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa
Alexander J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model
Brian VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Florian M. Wagenlehner et al.
CLINICAL INFECTIOUS DISEASES (2016)
Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model
Brian D. VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance
F. Docobo-Perez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Assessment of Outpatient and Inpatient Antibiotic Treatment Patterns and Health Care Costs of Patients with Complicated Urinary Tract Infections
Ralph M. Turner et al.
CLINICAL THERAPEUTICS (2015)
Urinary tract infections
Sampath Kumar et al.
DM DISEASE-A-MONTH (2015)
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Florian M. Wagenlehner et al.
LANCET (2015)
Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
Dmitri Iarikov et al.
INFECTIOUS DISEASES AND THERAPY (2015)
Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates
Pak-Leung Ho et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2013)
Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens
Drosos E. Karageorgopoulos et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Adverse events associated with intravenous fosfomycin
Amelie Florent et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
Fosfomycin: an old, new friend?
M. Popovic et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2010)
Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review
Matthew E. Falagas et al.
LANCET INFECTIOUS DISEASES (2010)
Management of Complicated Urinary Tract Infections in the Era of Antimicrobial Resistance
Mazen S. Bader et al.
POSTGRADUATE MEDICINE (2010)
Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies
Matthew E. Falagas et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Share Paper
